Why pharmaceutical shipments now require formal, PGA-supporting entry to move by mail — and where to find the FDA admissibility rules.
This page covers postal entry mechanics for pharmaceutical and health-product shipments — not Section 232 tariff rates. No published Section 232 tariff schedule for pharmaceuticals is covered in this guide; if one is later finalized, this page should be updated to reflect it. For the actual admissibility rules — what can and can't be mailed, and why — see FDA import rules for medicines and health products.
FDA-regulated products are Partner Government Agency (PGA) merchandise: the FDA requires supporting data before a shipment can clear, on top of ordinary customs data. Until recently, low-value mail shipments could largely skip this — FDA's last general exception for low-value FDA-regulated packages closed in July 2025.
October 22, 2026 — the date everything changes
Starting October 22, 2026, FDA-regulated mail shipments can no longer use the simplified postal entry process (the "IMDW" — International Mail Duty Worksheet). They must move through an ACE entry process that supports the required FDA (PGA) data — even for very small, low-value packages. There is no value threshold that exempts a shipment from this.
A pharmaceutical or health-product shipment can be perfectly admissible under FDA's rules and still be blocked from a simplified postal path once this cutover takes effect — the two questions are separate. Admissibility (is this product legal to bring in at all) is FDA's call; entry type (can it move through the postal process, or does it need a formal ACE entry) is a customs-mechanics question that now applies regardless of a product's admissibility status.
For shippers and posts, this means building in an assumption that FDA-regulated parcels need PGA data attached at entry, not an assumption that small or low-value packages skip review.
Disclaimer
This guide is for general informational purposes and does not constitute legal or customs advice. Consult a licensed customs broker or trade attorney for product-specific determinations.
Pharmaceuticals and postal entry
Pharmaceuticals and postal entry
Why pharmaceutical shipments now require formal, PGA-supporting entry to move by mail — and where to find the FDA admissibility rules.
This page covers postal entry mechanics for pharmaceutical and health-product shipments — not Section 232 tariff rates. No published Section 232 tariff schedule for pharmaceuticals is covered in this guide; if one is later finalized, this page should be updated to reflect it. For the actual admissibility rules — what can and can't be mailed, and why — see FDA import rules for medicines and health products.
Why this matters for postal shipments now
FDA-regulated products are Partner Government Agency (PGA) merchandise: the FDA requires supporting data before a shipment can clear, on top of ordinary customs data. Until recently, low-value mail shipments could largely skip this — FDA's last general exception for low-value FDA-regulated packages closed in July 2025.
Starting October 22, 2026, FDA-regulated mail shipments can no longer use the simplified postal entry process (the "IMDW" — International Mail Duty Worksheet). They must move through an ACE entry process that supports the required FDA (PGA) data — even for very small, low-value packages. There is no value threshold that exempts a shipment from this.
What it means for shipments
A pharmaceutical or health-product shipment can be perfectly admissible under FDA's rules and still be blocked from a simplified postal path once this cutover takes effect — the two questions are separate. Admissibility (is this product legal to bring in at all) is FDA's call; entry type (can it move through the postal process, or does it need a formal ACE entry) is a customs-mechanics question that now applies regardless of a product's admissibility status.
For shippers and posts, this means building in an assumption that FDA-regulated parcels need PGA data attached at entry, not an assumption that small or low-value packages skip review.
This guide is for general informational purposes and does not constitute legal or customs advice. Consult a licensed customs broker or trade attorney for product-specific determinations.
Was this page helpful?